Jazz Pharma Expands Again in Epilepsy With $820M Actio Bio Acquisition

Jazz Prescription drugs, maker of the blockbuster epilepsy drug Epidiolex, is buying Actio Biosciences and its lead drug in pivotal testing for a uncommon kind of epilepsy with no FDA-approved remedies. It’s Jazz’s second epilepsy deal previously 12 months.

The put up Jazz Pharma Expands Once more in Epilepsy With $820M Actio Bio Acquisition appeared first on MedCity Information.

Source link